second million, struggled, At quarter time of loss you, joining by reporting you proud the you We share results strong us. results. for thrived. period, for Good Today XX%. a while $X the but operating And our with second XXX% financial our very year everyone. businesses to prior we survived over thank narrowing many Thank I'm with when not were revenue up Yvonne. afternoon, quarter only
general of financial giving also time in We security balance a uncertainty. cash strengthened significantly our us have
Our consumer in to key create a visits eye without during customers ago to were year-over-year while strategic growth volume. care pandemic move a stopped. and unit channel Avenova direct their without proved allowed channel patient closed the offices supporting largely to physician leaving order ever sales This a homes specialists and virtually year prescription to to
quarter in beginning international our Second in driven network revenue was by personal to of ability when short on growth months the early KNXX supply. supply equipment capitalize pandemic was masks the protective our to health
with NovaBay here creating order fulfillment. in demonstrated Our infrastructure timely agility team quickly these the offer great masks in to
continues, a powerful very it a we including announce particularly pandemic the inception, fungi. of laboratory COVID-XX results anti-microbial effective virus. and the pathogens, Avenova's all solution have spray to types COVID-XX gratifying the independent of Since against from to variety viruses, be confirming known it's Avenova As bacteria highly wide that reputable kills a
we Now kills confirming Avenova the independent coronavirus the COVID-XX. results have from causes laboratory a reputable that highly
the all and Avenova skin. parts for made of skin These by hypochlorous acid, particularly Clorox, kill cleared transmission. disinfectants names that are to is with differentiator. virus, FDA for hypochlorous formulated repeatedly that sensitive day. eyes, disinfectants solution to be the completely is spray to on is only a use well-known body on is pure alike. non-toxic other the Lysol in manufactured many While susceptible the and nose and pure can designed everybody like Unlike be specifically the throughout significant Avenova and enough gentle around which Avenova remind products is I'd not some applied the acid Avenova familiar America are our like use is known mouth. COVID-XX
all concentration may to our really the like acid pharmaceutical products. of sufficiently like hypochlorous Most other products. to are are laboratory Avenova these surprising hypochlorous in that these of I'd note, apart a and high copycat results, acid sales As the these, warn test consumer favorably results. us we've both products grade like COVID-XX careful to reacting sets dispense an virus. times not cases Since In generic contain other and cautionary It's channels. resurgence be and quality consumers to from uptick consumers not physicians the in of given kill COVID-XX a not and physician announcing in the seen Avenova
years. to seeing brand having we're back after come doctors several prescribed Avenova our some not Additionally, for
for brand In shown currently other and new are to truly from addition orders fulfilling bulk new opportunity our bulk front expand now in to and grow orders have types customers, markets. doctors of PPE for Avenova the large they've us into institutions. These we our and we of us, and are regular medical that us
During reputation times, have low-quality with turbulent of the have claims valuable. products professionals skeptical many delivering thus our for effectiveness false healthcare marketplace. and and more has become flooded these much products become Consumers quality
team incorporate customers also program. of message quality means advertising current about to into is while cost-effective marketing digital our We create a us for our customer to base. virus-killing This are our with capability that working expanding awareness with Avenova's
and We media been York and City in New television have subway City more San Francisco kiosks, print. active other including signage, in advertising
We're business for process inclusion sheet submitting balance strong laboratory working future on The disinfectants. several EPA's will with of Avenova the review likely approved EPA's also weeks. are strategy. a our require towards Protection a test We also of results the significantly support to list Environmental to the strengthened Agency
outstanding and the in a sheet the by through second transaction. warrant completed were in warrants our renegotiate warrant eliminating related liability financing an and aftermarket the recently sold stabilization quarter, we P&L. and able resulting balance of to a our exercise swings large non-cash During program We very of successful stock most our
funds, we also requirements York will huge. listing is With with compliance the of This addition these continued Exchange. Stock the the maintain New of
be the the these of recently which kit we the has to We emergency and with demand the data is the continues There a we FDA strong review, test received the of securing authorization a submitting believe FDA EUA use for final kits. for ton we types EUA antibody we Lastly, kit. questions Fluorecare of this continue Since to round on for or actively have to work for requested continue SARS-CoV-X kit. test hopeful in be currently what provided. additional
I'll our more to financial to performance turn Andy Now, call review in the detail. over
